ArticleInternational journal of clinical and experimental pathology2008
Gene expression profiles associated with advanced pancreatic cancer.
Article in International journal of clinical and experimental pathology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Sirtuin 6 is required for the integrated stress response and resistance to inhibition of transcriptional cyclin-dependent kinases.Science translational medicine · 2023Article
- Review
- Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.Oncology letters · 2021Article
- Article
- Identification of novel therapeutic target genes and pathway in pancreatic cancer by integrative analysis.Medicine · 2017Article
- RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer.Oncotarget · 2017Article
- Identification of molecular biomarkers for pancreatic cancer with mRMR shortest path method.Oncotarget · 2017Article
- Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer.Drug design, development and therapy · 2015Review
- S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells.Clinical & experimental metastasis · 2013Article
- Molecular markers associated with outcome and metastasis in human pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2012Article
- Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.Cancer science · 2012Article
- DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.PloS one · 2012Article
- Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer.Molecular cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Few studies have addressed the expression profiles associated with progression of pancreatic cancer to advanced disease. Towards this end, we performed expression profiling of a series of normal pancreas, pancreatitis and cancer tissues representing early stage resected pancreatic cancers (stages pT2/T3), late stage unresectable cancers (stage pT4) and matched metastases to a variety of organ sites. Microarray data was analyzed using linear modeling of microarray data (LIMMA), and differentially expressed genes were subjected to Gene Set Enrichment Analysis (GSEA). While robust differences were found in primary cancers as compared to normal pancreatic tissues, no differences were found between primary cancers and metastases, whether using matched or unmatched samples. When resected pancreatic cancers were specifically compared to advanced pancreatic cancers, significant differences in gene expression were found associated with growth at the primary site. These differentially expressed genes were most prominent in gene classes that related to MAPK and Wnt pathway, metabolism, immune regulation, cell-cell and cell-matrix interactions within the infiltrating carcinoma. One candidate upregulated gene (MXI1) was validated as having increased expression in advanced stage (T4) carcinomas by real-time PCR (p<0.05) and immunolabeling (p<0.003). We conclude that in addition to the robust changes in expression that accompany pancreatic carcinogenesis additional specific changes occur in association with growth at the primary site. By contrast, metastatic spread is not accompanied by reproducible changes in gene expression. These findings add to our understanding of pancreatic cancer and offer new topics for investigation into the aggressive nature of this deadly tumor type.
Indexed as
Identifiers
18784821PMC2480531W29229010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.